International Journal of Cardiovascular Sciences. 05/ago/2024;37:e20230153.

Genetic Testing in Cardiomyopathy: Decoding Molecular Underpinnings and Influencing Treatment Decisions

Silas Ramos Furquim ORCID logo , Layara Fernanda Vicente Pereira Lipari ORCID logo , Fernanda Almeida Andrade ORCID logo , Vinícius Machado Correia ORCID logo , Natália Quintella Sangiorgi Olivetti ORCID logo , Lucas Vieira Lacerda Pires ORCID logo , Luciana Sacilotto ORCID logo , Fábio Fernandes ORCID logo , José Eduardo Krieger ORCID logo

DOI: 10.36660/ijcs.20230153

Abstract

Cardiomyopathy is characterized by structural and functional abnormalities in the heart muscle that are not influenced by coronary disease, hypertension, valve disease, or congenital heart defects. Genetic testing, which helps diagnose the molecular bases of cardiomyopathy, can affect prognostication and clinical decisions. Recent guidelines advocate classifying cardiomyopathies based on phenotypic categories, which encompass a range of clinical presentations, underlying causes, and outcomes. Beyond deepening our grasp of the disease, genetic testing can distinguish between diseases with similar presentations, known as genocopies, which can profoundly influence treatment decisions. Genetic testing is also essential for reproductive counseling and risk evaluation among family members. Combined with advanced imaging techniques such as magnetic resonance imaging, genetic investigation offers a comprehensive understanding of the disease. Thus, as the nature of cardiomyopathies continues to be unraveled, cardiologists must stay updated on advances in genetic testing and their practical applications.

Genetic Testing in Cardiomyopathy: Decoding Molecular Underpinnings and Influencing Treatment Decisions

Comentários

Pular para o conteúdo